|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
KR20030064275A
(ko)
|
2000-06-29 |
2003-07-31 |
메르크 파텐트 게엠베하 |
면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
|
|
WO2002085923A2
(en)
|
2001-04-19 |
2002-10-31 |
The Scripps Research Institute |
In vivo incorporation of unnatural amino acids
|
|
EP2410331B1
(en)
|
2003-06-18 |
2015-09-23 |
The Scripps Research Institute |
Aminoacyl-tRNA synthetase for aminoacylation tRNA with unnatural amino acids
|
|
EP1649004A4
(en)
|
2003-07-07 |
2008-04-09 |
Scripps Research Inst |
COMPOSITIONS WITH PAIRS OF ORTHOGONAL LYSYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF
|
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
EP2399893B1
(en)
|
2004-12-22 |
2018-08-15 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
CN105085313A
(zh)
|
2005-12-30 |
2015-11-25 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
AU2010206840B2
(en)
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
US20140302028A1
(en)
*
|
2011-11-18 |
2014-10-09 |
Merck Sharp & Dohme Corp. |
Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
|
|
EP2793947B1
(en)
|
2011-12-23 |
2021-02-03 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
PL3489254T3
(pl)
|
2012-04-30 |
2023-01-30 |
Biocon Limited |
Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
|
|
EP2890402B1
(en)
|
2012-08-31 |
2019-04-17 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US20160107999A1
(en)
|
2013-05-24 |
2016-04-21 |
Synaffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
CA2953287A1
(en)
|
2013-06-19 |
2014-12-24 |
Massachusetts Institute Of Technology |
In vivo targeting of cells with ligand-conjugated particles
|
|
CN105517577A
(zh)
|
2013-06-21 |
2016-04-20 |
先天制药公司 |
多肽的酶促偶联
|
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
US10266502B2
(en)
|
2014-01-24 |
2019-04-23 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
KR102410090B1
(ko)
|
2014-02-21 |
2022-06-16 |
넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 |
항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
WO2016115168A1
(en)
|
2015-01-12 |
2016-07-21 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
|
CN117659160A
(zh)
|
2015-09-11 |
2024-03-08 |
小利兰·斯坦福大学托管委员会 |
生物相关正交细胞因子/受体对
|
|
US20180126000A1
(en)
|
2016-06-02 |
2018-05-10 |
Abbvie Inc. |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
|
JP7128121B2
(ja)
|
2016-06-28 |
2022-08-30 |
ヴェンタナ メディカル システムズ， インク． |
Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
|
|
EP3272864A1
(en)
|
2016-07-20 |
2018-01-24 |
Paul Scherrer Institut |
Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
|
|
MY201482A
(en)
|
2017-04-03 |
2024-02-26 |
Hoffmann La Roche |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
CN110505883A
(zh)
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
|
|
AU2018259856B2
(en)
|
2017-04-28 |
2025-05-01 |
Ajinomoto Co., Inc. |
Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
WO2018215938A1
(en)
*
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
US20190023760A1
(en)
*
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
|
KR20240141853A
(ko)
|
2017-08-03 |
2024-09-27 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
NZ762376A
(en)
|
2017-09-19 |
2022-08-26 |
Scherrer Inst Paul |
Transglutaminase conjugation method and linker
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
JP2021505156A
(ja)
|
2017-12-06 |
2021-02-18 |
パンディオン・オペレーションズ・インコーポレイテッド |
標的化免疫寛容
|
|
IL275426B2
(en)
*
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
WO2019129053A1
(zh)
|
2017-12-26 |
2019-07-04 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
BR112020010536A2
(pt)
|
2018-01-25 |
2020-12-01 |
I-Mab Biopharma Us Limited |
molécula de fusão, proteína e célula isoladas, composição, e, método para tratar um câncer
|
|
EP3762406A2
(en)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Cytokine prodrugs
|
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
CN108503714A
(zh)
|
2018-04-10 |
2018-09-07 |
浙江科途医学科技有限公司 |
一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
|
|
KR102921757B1
(ko)
*
|
2018-06-14 |
2026-02-03 |
아지노모토 가부시키가이샤 |
항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염
|
|
JPWO2019240288A1
(ja)
*
|
2018-06-14 |
2021-07-26 |
味の素株式会社 |
抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
|
|
KR20250156190A
(ko)
|
2018-06-22 |
2025-10-31 |
큐진 인크. |
인터루킨-2 변이체 및 이의 사용 방법
|
|
MX2021000801A
(es)
|
2018-07-24 |
2021-04-12 |
BioNTech SE |
Agonistas de il2.
|
|
US20220041713A1
(en)
|
2018-09-18 |
2022-02-10 |
Pandion Operations, Inc |
Targeted immunotolerance
|
|
TWI840433B
(zh)
|
2018-10-29 |
2024-05-01 |
大陸商北京強新生物科技有限公司 |
新穎合理設計的蛋白質組合物
|
|
JPWO2020090979A1
(ja)
|
2018-10-31 |
2021-09-24 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
|
KR20210107714A
(ko)
|
2018-12-21 |
2021-09-01 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
인간 인터류킨-2 변이체 또는 이의 유도체
|
|
CA3128571A1
(en)
|
2019-03-19 |
2020-09-24 |
Paul Scherrer Institut |
Transglutaminase conjugation method with a glycine based linker
|
|
US20220233711A1
(en)
|
2019-05-17 |
2022-07-28 |
Shenzhen Enduring Biotech, Ltd. |
Bispecific t-cell engager with cleavable cytokines for targeted immunotherapy
|
|
WO2020252421A2
(en)
|
2019-06-14 |
2020-12-17 |
Cugene, Inc. |
Novel interleukin-2 variants and bifunctional fusion molecules thereof
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
CA3148505A1
(en)
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Novel il-2 fusion molecules
|
|
EP4013777A4
(en)
|
2019-08-15 |
2024-01-17 |
Cytimm Therapeutics, Inc. |
MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF
|
|
CN114853874B
(zh)
|
2019-09-10 |
2024-05-17 |
中国医学科学院北京协和医院 |
靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
|
|
MX2022007202A
(es)
*
|
2019-12-13 |
2022-10-07 |
Cugene Inc |
Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
|
|
CN121517534A
(zh)
|
2019-12-13 |
2026-02-13 |
辛德凯因股份有限公司 |
Il-2直向同源物及其使用方法
|
|
WO2021122866A1
(en)
|
2019-12-17 |
2021-06-24 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an il-7 variant
|
|
WO2021127487A2
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
AU2020412716A1
(en)
|
2019-12-23 |
2022-08-18 |
Sanofi |
Methods of preparing N6-((2-azidoethoxy)carbonyl)lysine
|
|
US11633488B2
(en)
|
2020-01-10 |
2023-04-25 |
Bright Peak Therapeutics Ag |
Modified IL-2 polypeptides and uses thereof
|
|
WO2021146436A2
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
|
CN118271419A
(zh)
|
2020-03-31 |
2024-07-02 |
韩美药品株式会社 |
新型免疫刺激il-2类似物
|
|
AU2021256936A1
(en)
|
2020-04-15 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
PE20231648A1
(es)
|
2020-04-22 |
2023-10-17 |
Merck Sharp And Dohme Llc |
CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO
|
|
WO2021222150A2
(en)
|
2020-04-28 |
2021-11-04 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|
|
US20240067727A1
(en)
|
2020-12-17 |
2024-02-29 |
Ose Immunotherapeutics |
Bifunctional anti-pd1/il-7 molecules
|
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
|
JP2024504372A
(ja)
|
2021-01-22 |
2024-01-31 |
エルピス・バイオファーマシューティカルズ |
抗ｐｄ－ｌ１モノクローナル抗体及びインターロイキン１５（ｉｌ－１５）、インターロイキン１５受容体１５アルファまたはインターロイキン２との融合タンパク質
|